📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. The written patient narratives for every death, serious adverse event, and adverse-event discontinuation in the pivotal trial — the ICH E3 §16.3 appendix to the CSR.

Why it exists. A real CSR does not just tabulate serious events; it tells each one as a story (who the subject was, what happened, what was done, and whether the drug was to blame). Here the 2 deaths, 10 SAEs, and 9 AE-discontinuations are data-anchored counts, narrated to be consistent with an older T2DM population — none attributed to the drug.

How it is produced here. The numbers come straight from the study's simulated Phase 3 dataset — they are calculated from the data, not typed in by hand. That is why you see the same figures repeated across the protocol, the analysis plan, the report, and the summaries: they all read from the same source.

Format & governing standard. —

Patient Narratives — Deaths, Serious Adverse Events, and Adverse-Event Discontinuations — GLPI103-301

Field	Value
Document ID	CSR-301-N (Appendix 16.3)
Version	1.0
Status	Final
Study No.	GLPI103-301
CDISC STUDYID	GLPI103
Sponsor	Virtual Biopharma Inc.
CTD location	Module 5.3.5.1 — CSR-301 Appendix 16.3 (Patient Narratives)
Standard(s)	ICH E3 §12.3.2 & Appendix 16.3 (narratives of deaths, other serious/significant AEs)
Confidentiality	Confidential

[MOCK — illustrative] The pivotal Phase-3 dataset records 2 deaths, 10 serious adverse events (SAEs), and 9 adverse-event-related discontinuations (CSR-301 §10.1, §12.5; outputs/). The event counts, causality assessments, and arm distribution are data-anchored; the individual clinical narrative detail below (ages, histories, day-of-onset) is illustrative and constructed to be consistent with those counts and with an older T2DM population. Subject identifiers are representative (USUBJID form GLPI103-3xxxx).

Change History

Version	Date	Author	Summary of Change
1.0	2026-07-05	Medical / Safety	Initial patient-narrative appendix (deaths, SAEs, AE-discontinuations) supporting CSR-301

Abbreviations

AE adverse event · SAE serious adverse event · TEAE treatment-emergent AE · MI myocardial infarction · T2DM type 2 diabetes mellitus · IP investigational product.

1. Purpose and Conventions

This appendix provides written narratives, per ICH E3, for every death and other serious adverse event, and for adverse events leading to discontinuation of investigational product. Each narrative states the subject's age/sex/relevant history, the event and its seriousness criteria, temporal relationship to dosing, action taken with IP, treatment given, outcome, and the investigator's and sponsor's causality assessment. Consistent with CSR-301 §12.5, no death and no SAE was assessed as related to investigational product; events are consistent with the background morbidity of an older population with established T2DM and cardiovascular risk.

2. Deaths (n = 2)

2.1 Subject GLPI103-30217 — GLPI-103 IV — fatal myocardial infarction

A 68-year-old man with a 14-year history of T2DM, hypertension, dyslipidaemia, and prior smoking, randomized to GLPI-103 IV, experienced sudden cardiac death attributed to acute myocardial infarction on Day 196. He had completed titration and was on maintenance dosing without prior cardiac symptoms on study. The event met the seriousness criterion of death. IP was permanently discontinued (subject deceased). The investigator and sponsor assessed the event as not related to IP and consistent with the subject's established cardiovascular risk profile; the DSMB reviewed the case and recommended continuation without modification (TMF-DSMB minutes).

2.2 Subject GLPI103-30588 — Semaglutide (active control) — fatal cerebrovascular accident

A 71-year-old woman with a 16-year history of T2DM, atrial fibrillation, and hypertension, randomized to oral semaglutide, died following an ischaemic stroke on Day 274. The event met the seriousness criterion of death. IP was permanently discontinued. The investigator and sponsor assessed the event as not related to IP; the event occurred in the active-comparator arm and was consistent with the subject's cerebrovascular risk. The DSMB reviewed the case with no safety concern raised.

3. Other Serious Adverse Events (n = 8 non-fatal; 10 SAEs total)

The eight non-fatal SAEs were distributed without pattern across the three arms and none was assessed as related to IP. Representative narratives:

3.1 Subject GLPI103-30104 — GLPI-103 IV — acute cholecystitis

A 61-year-old woman with obesity and cholelithiasis developed acute cholecystitis on Day 121, requiring hospitalization and laparoscopic cholecystectomy (seriousness: hospitalization). IP was interrupted and resumed after recovery. Assessed as not related to IP; gallbladder disease is a recognized background risk in this population and a class consideration monitored under the RMP.

3.2 Subject GLPI103-30346 — GLPI-103 Oral — community-acquired pneumonia

A 66-year-old man was hospitalized for pneumonia on Day 88 (seriousness: hospitalization); he recovered with antibiotics and continued IP. Assessed as not related to IP.

3.3 Subject GLPI103-30512 — Semaglutide — acute pancreatitis

A 59-year-old man with hypertriglyceridaemia was hospitalized with acute pancreatitis on Day 150 (seriousness: hospitalization); IP was permanently discontinued and the subject recovered. Assessed by the investigator as possibly related (class-labelled event) in the active-comparator arm; adjudicated as consistent with the comparator's known profile. Pancreatitis is a monitored AESI across the program (PROT-301 §10; RMP).

3.4 Representative additional SAEs

The remaining serious events comprised hospitalizations for unstable angina, a fall with hip fracture, a severe hypoglycaemic episode (semaglutide arm, in a subject on background sulfonylurea), and an elective orthopaedic procedure. Each met a seriousness criterion (hospitalization), none was assessed as related to GLPI-103, and outcomes were recovery/resolution except where noted. Full line listings are provided in CSR-301 Appendix 16.2 (from the ADaM ADAE dataset).

4. Adverse Events Leading to Discontinuation of IP (n = 9)

Nine subjects discontinued IP because of an adverse event (CSR-301 §10.1). The predominant reason was persistent gastrointestinal intolerance (nausea and/or vomiting) despite titration and dose modification, occurring most often in the higher-exposure GLPI-103 IV arm — consistent with the efficacy–tolerability gradient described in CSR-301 §12.3. Representative narratives:

4.1 Subject GLPI103-30129 — GLPI-103 IV — nausea/vomiting

A 57-year-old woman experienced recurrent moderate nausea and vomiting from Day 15 that did not resolve with the protocol titration and antiemetic supportive care; IP was discontinued on Day 43. The events were mild-to-moderate, non-serious, assessed as related to IP (expected gastrointestinal reaction; IB-001 §7 RSI), and resolved after discontinuation.

4.2 Subject GLPI103-30402 — GLPI-103 Oral — nausea with weight-related anorexia

A 63-year-old man discontinued on Day 57 for persistent nausea and reduced oral intake; events were non-serious, assessed as related, and resolved on withdrawal.

4.3 Remaining AE-discontinuations

The remaining discontinuations were for gastrointestinal intolerance (n=5, predominantly IV arm), injection-site reaction (n=1, IV arm), and one non-related event. All were non-serious, expected, and resolved after IP withdrawal; none was accompanied by a laboratory signal of organ toxicity (CSR-301 §12.6).

5. Cross-References

CSR-301 §10.1 (disposition), §12.3–12.6 (adverse events, AESI, deaths/SAEs, labs); ISS-301 (integrated safety); ADaM ADAE/ADSL listings (CSR-301 Appendix 16.2); TMF-DSMB (charter & minutes); RMP-EU/US/KR (risk minimization); IB-001 §7 (Reference Safety Information).